following an abbreviated submission:
diroximel fumarate (Vumerity®) is accepted for use within NHSScotland.
Indication under review: treatment of adult patients with relapsing remitting multiple sclerosis.
Diroximel fumarate provides an additional treatment choice in the therapeutic class of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activators.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
Download detailed advice725KB (PDF)
- Medicine name:
- diroximel fumarate (Vumerity)
- SMC ID:
For treatment of adult patients with relapsing remitting multiple sclerosis (RRMS)
- Pharmaceutical company
- Biogen Idec Ltd
- BNF chapter
- Central nervous system
- Submission type
- Date advice published
- 07 February 2022